Our anticancer research focuses on targeted therapies that interfere with specific signaling pathways and/or enzymes involved in metabolic adaptations of cancer cells.
-
Hedgehog (Hh) Signaling Pathway: Aberrant activation of the Hh pathway is a driver in many cancers. We focus on targeting key components of this pathway, including the Smoothened receptor (Smo) and especially downstream effectors like Gli1. We utilize structure-based design to develop inhibitors that can block this signaling cascade. Particular attention is given to the use of natural compounds as a source of bioactive leads.
-
Targeting Cancer Metabolism & Microenvironment:
- ALDHs (Aldehyde Dehydrogenases) are often markers of cancer stem cells (CSCs) and contribute to chemotherapy resistance.
- CAs (Carbonic Anhydrases) are involved in pH regulation and adaptation to hypoxia in tumors.